Solid Tumors clinical trials
Showing 551–600 of 1,133 active trials. Describe your situation to see which ones look like a fit.
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Study of XB010 in Subjects With Solid Tumors
- A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
- Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
- Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
- CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- A Study of YL201 in Patients With Advanced Solid Tumors
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Brodalumab in the Treatment of Immune-Related Adverse Events
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- IDOV-Immune for Advanced Solid Tumors
- Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- A Study of PHST001 in Advanced Solid Tumors
- S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of TAK-505 in Adults With Solid Tumors
- A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- A Clinical Study of YL205 in Patients With Advanced Solid Tumors
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.